STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer

被引：30

作者：

Attili, Ilaria ^{[1
]}

Karachaliou, Niki ^{[2
,3
]}

Bonanno, Laura ^{[4
]}

Berenguer, Jordi ^{[2
]}

Bracht, Jillian ^{[2
]}

Codony-Servat, Jordi ^{[2
]}

Codony-Servat, Carles ^{[2
]}

Ito, Masaoki ^{[2
,5
]}

Rosell, Rafael ^{[2
,6
,7
,8
]}

机构：

[1] Univ Padua, Dept Surg Oncol & Gastroenterol, Via Giustiniani 2,53, I-35128 Padua, Italy

[2] Quiron Dexeus Univ Inst, Coyote Res Grp, Lab Mol Biol, Pangaea Oncol, Barcelona, Spain

[3] Univ Hosp Sagrat Cor, Inst Oncol Dr Rosell IOR, Barcelona, Spain

[4] IRCCS, Ist Oncol Veneto, Padua, Italy

[5] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Surg Oncol, Hiroshima, Japan

[6] Quiron Dexeus Univ Inst, Inst Oncol Dr Rosell IOR, Barcelona, Spain

[7] Inst Invest Ciencies Germans Trias & Pujol, Badalona, Spain

[8] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Badalona, Spain

来源：

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2018年 / 10卷

关键词：

biomarkers; immunotherapy; lung cancer; PD-L1; STAT3; NF-KAPPA-B; PD-L1; EXPRESSION; OPEN-LABEL; SERINE PHOSPHORYLATION; DENDRITIC CELLS; ACTIVATION; INHIBITION; RESISTANT; DOCETAXEL; NIVOLUMAB;

D O I：

10.1177/1758835918763744

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immune checkpoint blockade has modified the treatment landscape for many types of tumors, including lung cancer. Still our knowledge on the biology of the interaction between tumor cells and the microenvironment is limited, preventing the optimal use of these new compounds and the maximum benefit that the patients can derive from them. We have actively worked on the role of STAT3, a transcriptional factor that causes innate resistance to targeted therapies in oncogene-addicted tumors. In this short review we take the opportunity to express our opinion and review existing knowledge on the immune role of STAT3 and the possible implications that this may have for the discovery of new biomarkers to predict response to immunotherapy, as well as new partners to combine with and increase the efficacy of immune checkpoint inhibitors.

引用

页数：9

共 85 条

[11] An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1 [J].

Cogswell, John ;

Inzunza, H. David ;

Wu, Qiuyan ;

Feder, John N. ;

Mintier, Gabe ;

Novotny, James ;

Cardona, Diana M. .

MOLECULAR DIAGNOSIS & THERAPY, 2017, 21 (01) :85-93

[12] PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients [J].

D'Incecco, A. ;

Andreozzi, M. ;

Ludovini, V. ;

Rossi, E. ;

Capodanno, A. ;

Landi, L. ;

Tibaldi, C. ;

Minuti, G. ;

Salvini, J. ;

Coppi, E. ;

Chella, A. ;

Fontanini, G. ;

Filice, M. E. ;

Tornillo, L. ;

Incensati, R. M. ;

Sani, S. ;

Crino, L. ;

Terracciano, L. ;

Cappuzzo, F. .

BRITISH JOURNAL OF CANCER, 2015, 112 (01) :95-102

[13] Serine phosphorylation of STATs [J].

Decker, T ;

Kovarik, P .

ONCOGENE, 2000, 19 (21) :2628-2637

[14]

Demuth C, 2017, ONCOTARGET, V8, P68221, DOI 10.18632/oncotarget.19920

[15] Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity [J].

Dorand, R. Dixon ;

Nthale, Joseph ;

Myers, Jay T. ;

Barkauskas, Deborah S. ;

Avril, Stefanie ;

Chirieleison, Steven M. ;

Pareek, Tej K. ;

Abbott, Derek W. ;

Stearns, Duncan S. ;

Letterio, John J. ;

Huang, Alex Y. ;

Petrosiute, Agne .

SCIENCE, 2016, 353 (6297) :399-403

[16] MET-Independent Lung Cancer Cells Evading EGFR Kinase Inhibitors Are Therapeutically Susceptible to BH3 Mimetic Agents [J].

Fan, Weiwen ;

Tang, Zhe ;

Yin, Lihong ;

Morrison, Bei ;

Hafez-Khayyata, Said ;

Fu, Pingfu ;

Huang, Honglian ;

Bagai, Rakesh ;

Jiang, Shan ;

Kresak, Adam ;

Howell, Scott ;

Vasanji, Amit ;

Flask, Chris A. ;

Halmos, Balazs ;

Koon, Henry ;

Ma, Patrick C. .

CANCER RESEARCH, 2011, 71 (13) :4494-4505

[17] Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial [J].

Fehrenbacher, Louis ;

Spira, Alexander ;

Ballinger, Marcus ;

Kowanetz, Marcin ;

Vansteenkiste, Johan ;

Mazieres, Julien ;

Park, Keunchil ;

Smith, David ;

Artal-Cortes, Angel ;

Lewanski, Conrad ;

Braiteh, Fadi ;

Waterkamp, Daniel ;

He, Pei ;

Zou, Wei ;

Chen, Daniel S. ;

Yi, Jing ;

Sandler, Alan ;

Rittmeyer, Achim .

LANCET, 2016, 387 (10030) :1837-1846

[18] The role of STAT3 in tumor-mediated immune suppression [J].

Ferguson, Sherise D. ;

Srinivasan, Visish M. ;

Heimberger, Amy B. .

JOURNAL OF NEURO-ONCOLOGY, 2015, 123 (03) :385-394

[19] Immunoproteasomes: Structure, Function, and Antigen Presentation [J].

Ferrington, Deborah A. ;

Gregerson, Dale S. .

PROTEASOMAL SYSTEM IN AGING AND DISEASE, 2012, 109 :75-112

[20] EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis [J].

Gainor, Justin F. ;

Shaw, Alice T. ;

Sequist, Lecia V. ;

Fu, Xiujun ;

Azzoli, Christopher G. ;

Piotrowska, Zofia ;

Huynh, Tiffany G. ;

Zhao, Ling ;

Fulton, Linnea ;

Schultz, Katherine R. ;

Howe, Emily ;

Farago, Anna F. ;

Sullivan, Ryan J. ;

Stone, James R. ;

Digumarthy, Subba ;

Moran, Teresa ;

Hata, Aaron N. ;

Yagi, Yukako ;

Yeap, Beow Y. ;

Engelman, Jeffrey A. ;

Mino-Kenudson, Mari .

CLINICAL CANCER RESEARCH, 2016, 22 (18) :4585-4593

← 1 2 3 4 5 6 7 8 9 →